What are the key features of latent hepatitis C. How does hepatitis C progress from acute to chronic infection. What are the long-term complications of chronic hepatitis C. How is hepatitis C diagnosed and treated. Can hepatitis C be prevented.

Understanding Hepatitis C: A Silent Epidemic

Hepatitis C virus (HCV) infection is a major global health concern, affecting millions of people worldwide. Often referred to as a “silent epidemic,” hepatitis C can progress undetected for years, causing significant liver damage before symptoms become apparent. This article delves into the intricacies of latent hepatitis C, exploring its symptoms, causes, treatment options, transmission routes, and the current state of vaccine development.

The Clinical Spectrum of Hepatitis C

Hepatitis C presents a diverse clinical spectrum, ranging from acute infection to chronic liver disease. Understanding this spectrum is crucial for early detection and effective management of the condition.

Acute Hepatitis C

Acute hepatitis C refers to the initial phase of infection, which typically occurs within the first six months after exposure to the virus. What are the characteristics of acute hepatitis C? The infection has an average incubation period of 7 weeks, though it can range from 4 to 20 weeks. Notably, only about one-third of patients with acute hepatitis C experience symptoms or develop jaundice.

During the acute phase, serum aminotransferase levels often increase more than tenfold above normal. As symptoms subside, these levels gradually return to the normal range. It’s important to note that antibodies to HCV may not always be present at the onset of symptoms, making early diagnosis challenging.

Chronic Hepatitis C

A critical aspect of hepatitis C is its high rate of progression to chronic infection. Approximately 85% of individuals with acute HCV infection develop chronic hepatitis C. In these cases, HCV RNA remains detectable in the blood, and about two-thirds of patients continue to have elevated aminotransferase levels, typically 1.5 to 10 times the upper limit of normal.

The course of chronic hepatitis C varies significantly among individuals. Less than 20% of patients experience noticeable symptoms, which are often intermittent, vague, and nonspecific. Common complaints include malaise and easy fatiguability.

Symptoms and Manifestations of Hepatitis C

Hepatitis C is often referred to as a “silent” disease due to its frequently asymptomatic nature, especially in the early stages. However, as the infection progresses, various symptoms and manifestations may emerge.

Common Symptoms

• Fatigue
• Mild to moderate abdominal pain
• Loss of appetite
• Nausea
• Muscle or joint pain
• Weight loss
• Itchy skin

Extrahepatic Manifestations

A small percentage of patients with chronic hepatitis C develop extrahepatic manifestations, which are conditions affecting organs other than the liver. These can include:

• Cryoglobulinemia: A condition where abnormal proteins in the blood thicken in cold temperatures, leading to skin rashes, joint pain, and kidney problems.
• Glomerulonephritis: Inflammation of the kidney’s filtering units, which can lead to kidney damage.
• Mixed cryoglobulinemia: A blood disorder that can cause skin lesions, joint pain, and kidney disease.
• Porphyria cutanea tarda: A disorder affecting skin pigmentation and liver function.
• Lichen planus: An inflammatory condition affecting the skin and mucous membranes.

Progression and Complications of Chronic Hepatitis C

Chronic hepatitis C can lead to severe liver damage over time. How does hepatitis C progress to more serious complications? The progression is often slow and insidious, with an estimated 20% to 30% of patients developing cirrhosis over a period of 20-30 years.

Cirrhosis

Cirrhosis is characterized by the replacement of healthy liver tissue with scar tissue, leading to impaired liver function. Once cirrhosis develops, symptoms become more common and severe. Patients may experience:

• Jaundice (yellowing of the skin and eyes)
• Weakness
• Muscle wasting
• Gastrointestinal bleeding
• Fluid accumulation in the abdomen (ascites)
• Mental confusion (hepatic encephalopathy)

Hepatocellular Carcinoma

Patients with cirrhosis due to chronic hepatitis C are at increased risk of developing hepatocellular carcinoma (HCC), a type of liver cancer. The annual risk of HCC in patients with HCV-related cirrhosis is approximately 1-4%.

Diagnosis and Monitoring of Hepatitis C

Early diagnosis and regular monitoring are crucial for effective management of hepatitis C. What are the key diagnostic tools for hepatitis C?

Antibody Testing

The initial screening test for HCV is an enzyme immunoassay (EIA) that detects antibodies to the virus. However, it’s important to note that antibodies may not be detectable until 8-12 weeks after infection.

HCV RNA Testing

If antibody testing is positive, a confirmatory test for HCV RNA is performed using polymerase chain reaction (PCR) technology. This test can detect the presence of the virus itself and is useful for confirming active infection and monitoring treatment response.

Liver Function Tests

Regular monitoring of liver enzymes, particularly alanine aminotransferase (ALT) and aspartate aminotransferase (AST), helps assess liver inflammation and damage.

Liver Biopsy and Non-invasive Fibrosis Assessment

While liver biopsy was traditionally the gold standard for assessing liver damage, non-invasive methods such as FibroScan (transient elastography) and blood-based fibrosis scores are now widely used to evaluate liver fibrosis and cirrhosis.

Treatment Strategies for Hepatitis C

The landscape of hepatitis C treatment has dramatically changed in recent years with the introduction of direct-acting antivirals (DAAs). What are the current treatment options for hepatitis C?

Direct-Acting Antivirals (DAAs)

DAAs are highly effective oral medications that target specific steps in the HCV life cycle. These drugs have revolutionized hepatitis C treatment, offering cure rates exceeding 95% for most genotypes with fewer side effects compared to older therapies.

Common DAA regimens include:

• Sofosbuvir/velpatasvir
• Glecaprevir/pibrentasvir
• Elbasvir/grazoprevir
• Ledipasvir/sofosbuvir

Treatment Duration and Monitoring

Treatment duration typically ranges from 8 to 12 weeks, depending on the specific regimen, HCV genotype, and presence of cirrhosis. During treatment, patients are monitored for side effects and treatment response. Sustained virologic response (SVR), defined as undetectable HCV RNA 12 weeks after completing treatment, is considered a cure.

Management of Advanced Liver Disease

For patients with advanced liver disease or cirrhosis, additional management strategies may be necessary, including:

• Regular screening for hepatocellular carcinoma
• Management of portal hypertension
• Treatment of ascites and hepatic encephalopathy
• Evaluation for liver transplantation in severe cases

Transmission and Prevention of Hepatitis C

Understanding the transmission routes of hepatitis C is crucial for prevention efforts. How is hepatitis C transmitted, and what are effective prevention strategies?

Transmission Routes

HCV is primarily transmitted through exposure to infected blood. Common routes of transmission include:

• Injection drug use (sharing needles or other drug paraphernalia)
• Healthcare-associated exposures (e.g., needle-stick injuries, inadequate sterilization of medical equipment)
• Mother-to-child transmission during childbirth
• Sexual contact (although less common)
• Sharing personal items that may have blood on them (e.g., razors, toothbrushes)

Prevention Strategies

Preventing hepatitis C involves a multi-faceted approach:

1. Screening and testing of high-risk populations
2. Implementation of universal precautions in healthcare settings
3. Harm reduction programs for injection drug users (e.g., needle exchange programs)
4. Education about safe sex practices
5. Screening of blood and organ donors
6. Proper sterilization of medical and dental equipment

The Quest for a Hepatitis C Vaccine

Despite significant advances in treatment, a preventive vaccine for hepatitis C remains elusive. Why is developing a hepatitis C vaccine challenging?

Challenges in Vaccine Development

Several factors complicate the development of an effective HCV vaccine:

• High genetic variability of the virus
• Ability of the virus to evade the immune system
• Lack of suitable animal models for testing
• Incomplete understanding of protective immunity against HCV

Current Research Efforts

Despite these challenges, research into HCV vaccines continues. Current approaches include:

• Recombinant protein vaccines
• Vector-based vaccines
• DNA vaccines
• Virus-like particle vaccines

While several vaccine candidates have shown promise in early-stage clinical trials, a commercially available HCV vaccine remains a future goal.

Living with Hepatitis C: Long-term Management and Quality of Life

For individuals living with hepatitis C, long-term management is crucial for maintaining health and quality of life. What strategies can help improve outcomes for people with hepatitis C?

Lifestyle Modifications

Adopting a healthy lifestyle can help support liver health and overall well-being:

• Avoiding alcohol consumption
• Maintaining a balanced, nutritious diet
• Regular exercise within individual limits
• Avoiding hepatotoxic medications and supplements
• Quitting smoking

Regular Medical Follow-up

Even after successful treatment, regular medical check-ups are important for monitoring liver health and detecting any potential complications early. This may include:

• Periodic liver function tests
• Ultrasound or other imaging studies to screen for liver cancer
• Assessment of liver fibrosis progression

Psychological Support

Living with a chronic condition like hepatitis C can have significant psychological impacts. Access to mental health support, support groups, and patient education programs can be beneficial for many individuals.

Global Efforts to Eliminate Hepatitis C

The World Health Organization (WHO) has set ambitious targets to eliminate viral hepatitis as a public health threat by 2030. What strategies are being employed to achieve this goal?

Increased Screening and Diagnosis

Efforts are underway to expand access to HCV testing, particularly among high-risk populations. This includes the development and implementation of rapid diagnostic tests and point-of-care testing.

Expanding Access to Treatment

Improving access to affordable DAAs is a key priority. This involves negotiations with pharmaceutical companies, development of generic versions of DAAs, and implementation of national hepatitis elimination programs.

Prevention Strategies

Comprehensive prevention strategies include:

• Improving blood safety
• Enhancing infection control in healthcare settings
• Expanding harm reduction services for people who inject drugs
• Raising public awareness about HCV transmission and prevention

Integration with Other Health Services

Integrating HCV services with other health programs, such as HIV services, maternal and child health programs, and primary healthcare, can improve overall efficiency and reach.

In conclusion, while latent hepatitis C remains a significant global health challenge, advancements in understanding, diagnosis, and treatment offer hope for improved outcomes. Continued research, public health efforts, and global cooperation are essential in the ongoing fight against this silent epidemic. As we work towards the goal of elimination, it’s crucial to remain vigilant in prevention efforts, expand access to testing and treatment, and support those living with hepatitis C in managing their health and well-being.

Hepatitis C: the clinical spectrum of disease

Review

. 1997 Sep;26(3 Suppl 1):15S-20S.

doi: 10.1002/hep.510260703.

J H Hoofnagle 
¹

Affiliations

Affiliation

• ¹ Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

• PMID:

  9305658

• DOI:

  10.1002/hep.510260703

Review

J H Hoofnagle.

Hepatology.

1997 Sep.

. 1997 Sep;26(3 Suppl 1):15S-20S.

doi: 10.1002/hep.510260703.

Author

J H Hoofnagle 
¹

Affiliation

• ¹ Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

• PMID:

  9305658

• DOI:

  10.1002/hep.510260703

Abstract

Hepatitis C virus (HCV) accounts for approximately 20% of cases of acute hepatitis, 70% of chronic hepatitis, and 30% of end-stage liver disease in the United States. The acute infection has an incubation period of 7 weeks (range, 4-20 weeks) and is symptomatic and icteric in only one third of patients. Serum aminotransferase levels generally increase greater than 10-fold elevated and as symptoms and signs resolve decrease into the normal range. Antibody to HCV is usually but not always present at the time of onset of symptoms. HCV RNA appears in the serum early during the incubation period, increases in titer and peaks at the time of symptoms, and then disappears in resolving disease. Importantly, 85% of patients with acute HCV infection develop chronic infection. In these patients, HCV RNA remains present and in approximately two thirds of patients, aminotransferases remain elevated in the range of 1.5- to 10-fold the upper limit of normal. The course of chronic hepatitis C is variable. Probably fewer than 20% of patients have symptoms and they are usually intermittent, vague, and nonspecific, largely being malaise and easy fatiguability. A small percentage of patients develop extrahepatic manifestations of hepatitis C, including cryoglobulinemia and glomerulonephritis. It is estimated that 20% to 30% of patients with chronic hepatitis C develop cirrhosis, but the process is generally slow and insidious. Once cirrhosis develops, symptoms are more common and the signs of end-stage liver disease can appear with jaundice, weakness, wasting, and gastrointestinal bleeding. Patients with cirrhosis are also at risk for developing hepatocellular carcinoma. Thus, this important liver disease has protean manifestations but is often insidious and can lead to end-stage liver disease despite the presence of few symptoms and signs of illness.

Similar articles

• Hepatitis C: the clinical spectrum of the disease.

  Marcellin P.

  Marcellin P.
  J Hepatol. 1999;31 Suppl 1:9-16. doi: 10.1016/s0168-8278(99)80368-7.
  J Hepatol. 1999.

  PMID: 10622554

  Review.

• Natural history of hepatitis C.

  Alberti A, Chemello L, Benvegnù L.

  Alberti A, et al.
  J Hepatol. 1999;31 Suppl 1:17-24. doi: 10.1016/s0168-8278(99)80369-9.
  J Hepatol. 1999.

  PMID: 10622555

  Review.

• Course and outcome of hepatitis C.

  Hoofnagle JH.

  Hoofnagle JH.
  Hepatology. 2002 Nov;36(5 Suppl 1):S21-9. doi: 10.1053/jhep.2002.36227.
  Hepatology. 2002.

  PMID: 12407573

  Review.

• NIH Consensus Statement on Management of Hepatitis C: 2002.

  [No authors listed]

  [No authors listed]
  NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46.
  NIH Consens State Sci Statements. 2002.

  PMID: 14768714

  Review.

• Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.

  Leone N, Rizzetto M.

  Leone N, et al.
  Minerva Gastroenterol Dietol. 2005 Mar;51(1):31-46.
  Minerva Gastroenterol Dietol. 2005.

  PMID: 15756144

  English, Italian.

See all similar articles

Cited by

• The Relationship Between Anti-HCV Screening and Clinical Features of Inpatients in Addiction Center.

  Karabulut S.

  Karabulut S.
  Noro Psikiyatr Ars. 2022 Aug 21;59(3):232-236. doi: 10.29399/npa.27965. eCollection 2022.
  Noro Psikiyatr Ars. 2022.

  PMID: 36160080
  Free PMC article.

• Hepatocytes infected with hepatitis C virus change immunological features in the liver microenvironment.

  Park SJ, Hahn YS.

  Park SJ, et al.
  Clin Mol Hepatol. 2023 Jan;29(1):65-76. doi: 10.3350/cmh.2022.0032. Epub 2022 Aug 12.
  Clin Mol Hepatol. 2023.

  PMID: 35957546
  Free PMC article.

  Review.

• Feasibility of Hepatitis C Elimination in China: From Epidemiology, Natural History, and Intervention Perspectives.

  Zhao Z, Chu M, Guo Y, Yang S, Abudurusuli G, Frutos R, Chen T.

  Zhao Z, et al.
  Front Microbiol. 2022 Jun 2;13:884598. doi: 10.3389/fmicb.2022.884598. eCollection 2022.
  Front Microbiol. 2022.

  PMID: 35722351
  Free PMC article.

  Review.

• Prevalence and risk factors for hepatitis c virus co-infection among human immunodeficiency virus-infected patients and effect of hepatitis c virus infection on acquired immunodeficiency syndrome cases at baseline.

  Yakubu A, Hali B, Maiyaki AS.

  Yakubu A, et al.
  Ann Afr Med. 2021 Oct-Dec;20(4):297-301. doi: 10.4103/aam.aam_65_20.
  Ann Afr Med. 2021.

  PMID: 34893569
  Free PMC article.

• Sexually Transmitted Infections Treatment Guidelines, 2021.

  Workowski KA, Bachmann LH, Chan PA, Johnston CM, Muzny CA, Park I, Reno H, Zenilman JM, Bolan GA.

  Workowski KA, et al.
  MMWR Recomm Rep. 2021 Jul 23;70(4):1-187. doi: 10.15585/mmwr.rr7004a1.
  MMWR Recomm Rep. 2021.

  PMID: 34292926
  Free PMC article.

See all “Cited by” articles

Publication types

MeSH terms

Substances

Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion

1. Pfaender S., Brown R.J., Pietschmann T. , Steinmann E. Natural reservoirs for homologs of hepatitis C virus. Emerg. Microbes Infect. 2014;3:e21. doi: 10.1038/emi.2014.19. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

2. Li H.C., Lo S.Y. Hepatitis C virus: Virology, diagnosis and treatment. World J. Hepatol. 2015;7:1377–1389. doi: 10.4254/wjh.v7.i10.1377. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

3. Pinter M., Trauner M., Peck-Radosavljevic M., Sieghart W. Cancer and liver cirrhosis: Implications on prognosis and management. ESMO Open. 2016;1:e000042. doi: 10.1136/esmoopen-2016-000042. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Khan A.A., Ahmad H., Saif N., Idrees M., Bajwa M.A. Frequency distribution of hepatitis in three districts of Hazara division. Asian J. Med. Sci. 2010;2:37–39. [Google Scholar]

5. Palumbo E. Pegylated interferon and ribavirin treatment for hepatitis C virus infection. Ther. Adv. Chronic Dis. 2011;2:39–45. doi: 10.1177/2040622310384308. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

6. Ghany M.G., Strader D.B., Thomas D.L., Seeff L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology. 2009;49:1335–1374. doi: 10.1002/hep.22759. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

7. Scheel T.K.H., Rice C.M. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat. Med. 2013;19:837–849. doi: 10.1038/nm.3248. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. Park S.H., Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity. 2014;40:13–24. doi: 10.1016/j.immuni.2013.12.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

9. Messina J.P., Humphreys I., Flaxman A., Brown A., Cooke G.S., Pybus O.G., Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87. doi: 10.1002/hep.27259. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

10. Barrett S. , Sweeney M., Crowe J. Host immune responses in hepatitis C virus clearance. Eur. J. Gastroenterol. Hepatol. 2005;17:1089–1097. doi: 10.1097/00042737-200510000-00013. [PubMed] [CrossRef] [Google Scholar]

11. Koziel M.J. Cellular immune responses against hepatitis C virus. Clin. Infect. Dis. 2005;41:S25–S31. doi: 10.1086/429492. [PubMed] [CrossRef] [Google Scholar]

12. Larrubia J.R., Moreno-Cubero E., Lokhande M.U., García-Garzón S., Lázaro A., Miquel J., Perna C., Sanz-de-Villalobos E. Adaptive immune response during hepatitis C virus infection. World J. Gastroenterol. 2014;20:3418–3430. doi: 10.3748/wjg.v20.i13.3418. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Elmore S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007;35:495–516. doi: 10.1080/01926230701320337. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

14. Barber G.N. Host defense, viruses and apoptosis. Cell Death Differ. 2001;8:113–126. doi: 10.1038/sj.cdd.4400823. [PubMed] [CrossRef] [Google Scholar]

15. Iannello A., Debbeche O., Martin E., Attalah L.H., Samarani S., Ahmad A. Viral strategies for evading antiviral cellular immune responses of the host. J. Leukoc. Biol. 2006;79:16–35. doi: 10.1189/jlb.0705397. [PubMed] [CrossRef] [Google Scholar]

16. Oldstone M.B.A. Viral persistence: Parameters, mechanisms and future predictions. Virology. 2006;344:111–118. doi: 10.1016/j.virol.2005.09.028. [PubMed] [CrossRef] [Google Scholar]

17. Mundt B., Kühnel F., Zender L., Paul Y., Tillmann H., Trautwein C., Manns M.P., Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 2003;17:94–96. doi: 10.1096/fj.02-0537fje. [PubMed] [CrossRef] [Google Scholar]

18. Silberstein E., Ulitzky L., Lima L.A., Cehan N., Teixeira-Carvalho A., Roingeard P., Taylor D.R. HCV-mediated apoptosis of hepatocytes in culture and viral pathogenesis. PLoS ONE. 2016;11:e0155708. doi: 10.1371/journal.pone.0155708. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

19. Park M.S., Kim S., Patel J., Hajdu C.H., Do R.K., Mannelli L., Babb J.S., Taouli B. Hepatocellular carcinoma: Detection with diffusion-weighted versus contrast-enhanced magnetic resonance imaging in pretransplant patients. Hepatology. 2012;56:140–148. doi: 10.1002/hep.25681. [PubMed] [CrossRef] [Google Scholar]

20. Hoshida Y., Fuchs B.C., Bardeesy N., Baumert T.F., Chung R.T. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J. Hepatol. 2014;61:S79–S90. doi: 10.1016/j.jhep.2014.07.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

21. Iken K., Huang L., Bekele H., Schmidt E.V., Koziel M.J. Apoptosis of activated CD4⁺ and CD8⁺ T cells is enhanced by co-culture with hepatocytes expressing hepatitis C virus (HCV) structural proteins through FasL induction. Virology. 2006;346:363–372. doi: 10.1016/j.virol.2005.11.017. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

22. Toubi E., Kessel A., Goldstein L. , Slobodin G., Sabo E., Shmuel Z., Zuckerman E. Enhanced peripheral T-cell apoptosis in chronic hepatitis C virus infection: Association with liver disease severity. J. Hepatol. 2001;35:774–780. doi: 10.1016/S0168-8278(01)00207-0. [PubMed] [CrossRef] [Google Scholar]

23. Muriel P. Role of free radicals in liver diseases. Hepatol. Int. 2009;3:526–536. doi: 10.1007/s12072-009-9158-6. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

24. Eguchi A., Wree A., Feldstein A.E. Biomarkers of liver cell death. J. Hepatol. 2014;60:1063–1074. doi: 10.1016/j.jhep.2013.12.026. [PubMed] [CrossRef] [Google Scholar]

25. Barathan M., Gopal K., Mohamed R., Ellegård R., Saeidi A., Vadivelu J., Ansari A.W., Rothan H.A., Ravishankar Ram M., Zandi K., et al. Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Apoptosis. 2015;20:466–480. doi: 10.1007/s10495-014-1084-y. [PubMed] [CrossRef] [Google Scholar]

26. Derhovanessian E., Solana R., Larbi A., Pawelec G. Immunity, ageing and cancer. Immun. Ageing. 2008;5:11. doi: 10.1186/1742-4933-5-11. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

27. Chou J.P., Effros R.B. T cell replicative senescence in human aging. Curr. Pharm. Des. 2013;19:1680–1698. [PMC free article] [PubMed] [Google Scholar]

28. Strioga M., Pasukoniene V., Characiejus D. CD8⁺ CD28⁻ and CD8⁺ CD57⁺ T cells and their role in health and disease. Immunology. 2011;134:17–32. doi: 10.1111/j.1365-2567.2011.03470.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

29. Effros R.B. The silent war of CMV in aging and HIV infection. Mech. Ageing Dev. 2016;158:46–52. doi: 10.1016/j.mad.2015.09.003. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

30. Janković V., Messaoudi I., Nikolich-Zugich J. Phenotypic and functional T-cell aging in rhesus macaques (Macacamulatta): Differential behavior of CD4 and CD8 subsets. Blood. 2003;102:3244–3251. doi: 10.1182/blood-2003-03-0927. [PubMed] [CrossRef] [Google Scholar]

31. Maue A.C., Yager E.J., Swain S.L., Woodland D.L., Blackman M.A., Haynes L. T-cell immunosenescence: Lessons learned from mouse models of aging. Trends Immunol. 2009;30:301–305. doi: 10.1016/j.it.2009.04.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

32. Fülöp T., Larbi A., Pawelec G. Human T cell aging and the impact of persistent viral infections. Front. Immunol. 2013;4:271. doi: 10.3389/fimmu.2013.00271. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Borkow G., Bentwich Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: Role of hyporesponsiveness and anergy. Clin. Microbiol. Rev. 2004;17:1012–1030. doi: 10.1128/CMR.17.4.1012-1030.2004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Palmer B.E., Blyveis N., Fontenot A.P., Wilson C.C. Functional and phenotypic characterization of CD57⁺CD4⁺ T cells and their association with HIV-1-induced T cell dysfunction. J. Immunol. 2005;175:8415–8423. doi: 10.4049/jimmunol.175.12.8415. [PubMed] [CrossRef] [Google Scholar]

35. Petrovas C., Chaon B., Ambrozak D.R., Price D.A., Melenhorst J.J., Hill B.J., Geldmacher C., Casazza J.P., Chattopadhyay P.K., Roederer M., et al. Differential association of programmed death-1 and CD57 with ex vivo survival of CD8⁺ T cells in HIV infection. J. Immunol. 2009;183:1120–1132. doi: 10.4049/jimmunol.0900182. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

36. Saeidi A., Chong Y.K., Yong Y.K., Tan H.Y., Barathan M., Rajarajeswaran J., Sabet N.S., Sekaran S.D., Ponnampalavanar S., Che K.F., et al. Concurrent loss of co-stimulatory molecules and functional cytokine secretion attributes leads to proliferative senescence of CD8⁺ T cells in HIV/TB co-infection. Cell. Immunol. 2015;297:19–32. doi: 10.1016/j.cellimm.2015.05.005. [PubMed] [CrossRef] [Google Scholar]

37. Sabbaj S., Heath S.L., Bansal A., Vohra S., Kilby J.M., Zajac A. J., Goepfert P.A. Functionally competent antigen-specific CD127 (hi) memory CD8⁺ T cells are preserved only in HIV-infected individuals receiving early treatment. J. Infect. Dis. 2007;195:108–117. doi: 10.1086/509510. [PubMed] [CrossRef] [Google Scholar]

38. Deeks S.G., Kitchen C.M., Liu L., Guo H., Gascon R., Narváez A.B., Hunt P., Martin J.N., Kahn J.O., Levy J., et al. Immune activation set point during early HIV infection predicts subsequent CD4⁺ T-cell changes independent of viral load. Blood. 2004;104:942–947. doi: 10.1182/blood-2003-09-3333. [PubMed] [CrossRef] [Google Scholar]

39. Chou J.P., Ramirez C.M., Wu J.E., Effros R.B. Accelerated aging in HIV/AIDS: Novel biomarkers of senescent human CD8⁺ T cells. PLoS ONE. 2013;8:e64702. doi: 10.1371/journal.pone.0064702. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

40. Maly K., Schirmer M. The story of CD4+ CD28⁻ T cells revisited: Solved or still ongoing? J. Immunol. Res. 2015;2015:348746. [PMC free article] [PubMed] [Google Scholar]

41. Focosi D., Bestagno M., Burrone O., Petrini M. CD57⁺ T lymphocytes and functional immune deficiency. J. Leukoc. Biol. 2010;87:107–116. doi: 10.1189/jlb.0809566. [PubMed] [CrossRef] [Google Scholar]

42. Ripa M., Chiappetta S., Tambussi G. Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence. 2017;8:508–528. doi: 10.1080/21505594.2017.1292197. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

43. Barathan M., Mohamed R., Vadivelu J., Chang L.Y., Saeidi A., Yong Y.K., Ravishankar Ram M., Gopal K., Velu V., Larsson M., et al. Peripheral loss of CD8⁺ CD161⁺⁺ TCRVα7·2⁺ mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur. J. Clin. Investig. 2016;46:170–180. doi: 10.1111/eci.12581. [PubMed] [CrossRef] [Google Scholar]

44. Luciano A.A., Lederman M.M., Valentin-Torres A., Bazdar D. A., Sieg S.F. Impaired induction of CD27 and CD28 predicts naive CD4 T cell proliferation defects in HIV disease. J. Immunol. 2007;179:3543–3549. doi: 10.4049/jimmunol.179.6.3543. [PubMed] [CrossRef] [Google Scholar]

45. Golden-Mason L., Burton J.R., Jr., Castelblanco N., Klarquist J., Benlloch S., Wang C., Rosen H.R. Loss of IL-7 receptor alpha-chain (CD127) expression in acute HCV infection associated with viral persistence. Hepatology. 2006;44:1098–1109. doi: 10.1002/hep.21365. [PubMed] [CrossRef] [Google Scholar]

46. Racanelli V., Leone P., Grakoui A. A spatial view of the CD8⁺ T-cell response: The case of, H.C.V. Rev. Med. Virol. 2011;21:347–357. doi: 10.1002/rmv.702. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Bengsch B., Martin B., Thimme R. Restoration of HBV-specific CD8⁺ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 2014;61:1212–1219. doi: 10.1016/j.jhep.2014. 07.005. [PubMed] [CrossRef] [Google Scholar]

48. Bucks C.M., Norton J.A., Boesteanu A.C., Mueller Y.M., Katsikis P.D. Chronic antigen stimulation alone is sufficient to drive CD8⁺ T cell exhaustion. J. Immunol. 2009;182:6697–6708. doi: 10.4049/jimmunol.0800997. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

49. Wherry E.J., Ha S.J., Kaech S.M., Haining W.N., Sarkar S., Kalia V., Subramaniam S., Blattman J.N., Barber D.L., Ahmed R. Molecular signature of CD8⁺ T cell exhaustion during chronic viral infection. Immunity. 2007;27:670–684. doi: 10.1016/j.immuni.2007.09.006. [PubMed] [CrossRef] [Google Scholar]

50. Jelley-Gibbs D.M., Dibble J.P., Filipson S., Haynes L., Kemp R.A., Swain S.L. Repeated stimulation of CD4 effector T cells can limit their protective function. J. Exp. Med. 2005;201:1101–1112. doi: 10.1084/jem.20041852. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

51. Pauken K.E., Wherry E.J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 2015;36:265–276. doi: 10.1016/j.it.2015.02.008. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

52. Okoye I.S., Houghton M., Tyrrell L., Barakat K., Elahi S. Coinhibitory receptor expression and immune checkpoint blockade: Maintaining a balance in CD8⁺ T cell responses to chronic viral infections and cancer. Front. Immunol. 2017;8:1215. doi: 10.3389/fimmu.2017.01215. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Schietinger A., Greenberg P.D. Tolerance and exhaustion: Defining mechanisms of T cell dysfunction. Trends Immunol. 2014;35:51–60. doi: 10.1016/j.it.2013.10.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Sumida Y., Niki E., Naito Y., Yoshikawa T. Involvement of free radicals and oxidative stress in NAFLD/NASH. Free Radic. Res. 2013;47:869–880. doi: 10.3109/10715762.2013.837577. [PubMed] [CrossRef] [Google Scholar]

55. Urbani S., Amadei B., Tola D., Massari M., Schivazappa S., Missale G. Ferrari CPD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol. 2006;80:11398–11403. doi: 10.1128/JVI.01177-06. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

56. Kasprowicz V., Schulze ZurWiesch J., Kuntzen T., Nolan B.E., Longworth S., Berical A., Blum J., McMahon C., Reyor L.L., Elias N., et al. High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8⁺ and CD4⁺ T cells during acute HCV infection, irrespective of clinical outcome. J. Virol. 2008;82:3154–3160. doi: 10.1128/JVI.02474-07. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

57. Hashimoto N., Shimoda S., Kawanaka H., Tsuneyama K., Uehara H., Akahoshi T., Kinjo N., Taketomi A., Shirabe K., Akashi K., et al. Modulation of CD4⁺ T cell responses following splenectomy in hepatitis C virus-related liver cirrhosis. Clin. Exp. Immunol. 2011;165:243–250. doi: 10.1111/j.1365-2249.2011.04393.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58. Fathy A.A., Khalefa K.A., El-Sabawy M.M., El Sharnoby A.A. , Galbt H.A. PD-1 expression on peripheral CD8⁺ T cells closely correlated with hepatitis C virus viral load in chronic hepatitis C patients. Menoufia Med. J. 2016;29:383–388. [Google Scholar]

59. Gerlach J.T., Diepolder H.M., Jung M.C., Gruener N.H., Schraut W.W., Zachoval R., Hoffmann R., Schirren C.A., Santantonio T., Pape G.R. Recurrence of hepatitis C virus after loss of virus-specific CD4⁺ T-cell response in acute hepatitis C. Gastroenterology. 1999;117:933–941. doi: 10.1016/S0016-5085(99)70353-7. [PubMed] [CrossRef] [Google Scholar]

60. Semmo N., Day C.L., Ward S.M., Lucas M., Harcourt G., Loughry A., Klenerman P. Preferential loss of IL-2-secreting CD4⁺ T helper cells in chronic HCV infection. Hepatology. 2005;41:1019–1028. doi: 10.1002/hep.20669. [PubMed] [CrossRef] [Google Scholar]

61. Raziorrouh B., Ulsenheimer A., Schraut W., Heeg M., Kurktschiev P., Zachoval R., Jung M.C., Thimme R., Neumann-Haefelin C., Horster S., et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4⁺ T cells in patients with chronic infection. Gastroenterology. 2011;141:1422–1431. doi: 10.1053/j.gastro.2011.07.004. [PubMed] [CrossRef] [Google Scholar]

62. Barathan M., Mohamed R., Vadivelu J., Chang L.Y., Vignesh R., Krishnan J., Sigamani P., Saeidi A., Ram M.R., Velu V., et al. CD8⁺ T cells of chronic HCV-infected patients express multiple negative immune checkpoints following stimulation with HCV peptides. Cell. Immunol. 2017;313:1–9. doi: 10.1016/j.cellimm.2016.12.002. [PubMed] [CrossRef] [Google Scholar]

63. Rojas J.M., Avia M., Martín V., Sevilla N. IL-10: A multifunctional cytokine in viral infections. J. Immunol. Res. 2017;2017:6104054. doi: 10.1155/2017/6104054. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

64. Kurioka A., Walker L.J., Klenerman P., Willberg C.B. MAIT cells: New guardians of the liver. Clin. Transl. Immunol. 2017;6:e132. doi: 10.1038/cti.2017.5. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

65. Xiao X., Cai J. Mucosal-associated invariant T cells: New insights into antigen recognition and activation. Front. Immunol. 2017;8:1540. doi: 10.3389/fimmu.2017.01540. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

66. Cianferoni A. Invariant natural killer T cells. Antibodies. 2014;3:16–36. doi: 10.3390/antib3010016. [CrossRef] [Google Scholar]

67. Kjer-Nielsen L., Patel O., Corbett A.J., Le Nours J., Meehan B., Liu L., Bhati M., Chen Z., Kostenko L., Reantragoon R., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. 2012;491:717–723. doi: 10.1038/nature11605. [PubMed] [CrossRef] [Google Scholar]

68. Wakao H., Fujita H. Toward the realization of cell therapy: The advent of MAIT cells from iPSCs. Cell Cycle. 2013;12:2341–2342. doi: 10.4161/cc.25706. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

69. Le Bourhis L., Martin E., Péguillet I., Guihot A., Froux N., Coré M., Lévy E., Dusseaux M., Meyssonnier V., Premel V., et al. Antimicrobial activity of mucosal-associated invariant T cells. Nat. Immunol. 2010;11:701–708. doi: 10.1038/ni. 1890. [PubMed] [CrossRef] [Google Scholar]

70. Gold M.C., Lewinsohn D.M. Mucosal associated invariant T cells and the immune response to infection. Microbes Infect. 2011;13:742–748. doi: 10.1016/j.micinf.2011.03.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

71. Ussher J.E., Klenerman P., Willberg C.B. Mucosal-associated invariant T-cells: New players in anti-bacterial immunity. Front. Immunol. 2014;5:450. doi: 10.3389/fimmu.2014.00450. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

72. Saeidi A., Ellegård R., Yong Y.K., Tan H.Y., Velu V., Ussher J.E., Larsson M., Shankar E.M. Functional role of mucosal-associated invariant T cells in HIV infection. J. Leukoc. Biol. 2016;100:305–314. doi: 10.1189/jlb.4RU0216-084R. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73. Le Bourhis L., Guerri L., Dusseaux M., Martin E., Soudais C., Lantz O. Mucosal-associated invariant T cells: Unconventional development and function. Trends Immunol. 2011;32:212–218. doi: 10.1016/j.it.2011.02.005. [PubMed] [CrossRef] [Google Scholar]

74. Simoni Y., Diana J., Ghazarian L., Beaudoin L., Lehuen A. Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: Are we close to reality? Clin. Exp. Immunol. 2013;171:8–19. doi: 10.1111/j.1365-2249.2012.04625.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

75. van Wilgenburg B., Scherwitzl I., Hutchinson E.C., Leng T., Kurioka A., Kulicke C., de Lara C., Cole S., Vasanawathana S., Limpitikul W., et al. MAIT cells are activated during human viral infections. Nat. Commun. 2016;7:11653. doi: 10.1038/ncomms11653. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

76. Hengst J., Strunz B., Deterding K., Ljunggren H.G., Leeansyah E., Manns M.P., Cornberg M., Sandberg J.K., Wedemeyer H., Björkström N.K. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. Eur. J. Immunol. 2016;46:2204–2210. doi: 10.1002/eji. 201646447. [PubMed] [CrossRef] [Google Scholar]

77. Spaan M., Hullegie S.J., Beudeker B.J., Kreefft K., van Oord G.W., Groothuismink Z.M., van Tilborg M., Rijnders B., de Knegt R.J., Claassen M.A., et al. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/HIV co-infection and do not recover during therapy. PLoS ONE. 2016;11:e0159243. doi: 10.1371/journal.pone.0159243. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

78. Bolte F.J., O’Keefe A.C., Webb L.M., Serti E., Rivera E., Liang T.J., Ghany M., Rehermann B. Intra-hepatic depletion of mucosal-associated invariant T cells in hepatitis C virus-induced liver inflammation. Gastroenterology. 2017;153:1392–1403. doi: 10.1053/j.gastro.2017.07.043. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

79. Shrivastava S., Steele R., Ray R., Ray R.B. MicroRNAs: Role in hepatitis C virus pathogenesis. Genes Dis. 2015;2:35–45. doi: 10.1016/j.gendis.2015.01.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

80. Bandiera S., Pernot S., El Saghire H., Durand S.C., Thumann C., Crouchet E., Ye T., Fofana I., Oudot M.A., Barths J., et al. HCV-induced up-regulation of miR-146a-5p in hepatocytes promotes viral infection and deregulates metabolic pathways associated with liver disease pathogenesis. J. Virol. 2016;90:6387–6400. doi: 10.1128/JVI.00619-16. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

81. Bandiera S., Pfeffer S., Baumert T.F., Zeisel M.B. miR-122—A key factor and therapeutic target in liver disease. J. Hepatol. 2015;62:448–457. doi: 10.1016/j.jhep.2014.10.004. [PubMed] [CrossRef] [Google Scholar]

LATENT HEPATITIS B INFECTION | Tupoleva

1. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57:167-185.

2. Raimondo G., Allain J. P., Brunetto M. R. et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008; 49:652-657.

3. Cacciola I., Pollicino T., Squadrito G. et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341:22-26. doi: 10.1056/NEJM199907013410104.

4. Wasley A., Kruszon-Moran D., Kuhnert W. et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis 2010; 202:192-201.

5. Lopatkina TN, Volchkova EV, Abdurakhmanov DT et al. Reactivation of HBV infection in patients with lymphoma. Medical Council 2013; 5-6:40-45.

6. Raimondo G., Caccamo G., Filomia R. et al. Occult HBV infection. Semin Immunopathol 2013; 35:39-52. doi:10.1007/s00281-012-0327-7.

7. Raimondo G., Pollicino T., Cacciola I. et al. Occult hepatitis B virus infection. J Hepatol 2007; 46:160-170.

8. Pollicino T., Raffa G., Costantino L. et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007; 45:277-285. doi:10.1002/hep.21529.

9. Torbenson M. , Thomas D. L. Occult hepatitis B. Lancet Infect Dis 2002; 2:479-486.

10. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50:22742. doi:10.1016/j.jhep.2008.10.001.

11. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol 2005; 42:302-308. doi:10.1016/j.jhep.2004.12.015.

12. Penna A., Artini M., Cavalli A. et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98:1185-1194. doi:10.1172/JCI118902.

13. Rehermann B., Ferrari C., Pasquinelli C. et al. The hepatitis B virus persists for decades after patients recovering from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2:1104-1108. doi: 10.1038/nm1096-1104.

14. Pollicino T., Squadrito G., Cerenzia G. et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126:102-110. doi:10.1053/j.gastro.2003.10.048.

15. Wong D. K., Huang F. Y., Lai C. L. et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54:829-836. doi:10.1002/hep.24551.

16. Zerbini A., Pilli M., Boni C. et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008; 134:1470-1481. https://doi.org/10.1053/j.gastro.2008.02.017.

17. Mulrooney-Cousins ​​P. M., Michalak T. I. Persistent occult hepatitis B virus infection: experimental findings and clinical implications. World J Gastroenterology 2007; 13:5682-5686. DOI: 10.3748/wjg.v13.i43.5682.

18. Bes M., Vargas V., Piron M. et al. T cell responses and viral variability in blood donation candidates with occult hepatitis B infection. J Hepatol 2012; 56:765-774. doi: 10.1016/j.jhep.2011.11.011.

19. Stuart C., James W. T., Velema M. et al. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009; 81:441-445. DOI: 10.1002/jmv.21422.

20. Martin C. M., Welge J. A., Shire N. J. et al. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals. Cytokine 2009; 47:194-198. https://doi.org/10.1016/j.cyto.2009.06.005

21. Guidotti L. G., Chisari F. V. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91. DOI:10.1146/annurev.immunol.19.1.65.

22. Lucifora J., Durantel D., Testoni B. et al. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology 2010; 51:63-72. DOI: 10.1002/hep.23230.

23. Levrero M., Pollicino T., Petersen J. et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009: 51:581-592. DOI: https://doi. org/10.1016/j.jhep.2009.05.022.

24. Lieberman P. M. Chromatin organization and virus gene expression. J Cell Physiol 2008; 216:295-302. DOI: 10.1002/jcp.21421.

25. Bloom D. C., Giordani N. V., Kwiatkowski D. L. Epigenetic regulation of latent HSV-1 gene expression. Biochim Biophys Acta 2010; 1799:246-256. https://doi.org/10.1016/j.bbagrm.2009.12.001.

26. Takacs M., Banati F., Koroknai A. et al. Epigenetic regulation of latent Epstein—Barr virus promoters. Bioch Bioph Acta 2010; 1799:228-235. https://doi.org/10.1016/j.bbagrm.2009.10.005

27. Cougot D., Allemand E., Riviere L. et al. Inhibition of PP1 phosphatase activity by HBx: A mechanism for the activation of hepatitis B virus transcription. Sci Signal 2012; 5(205):ra1. DOI: 10.1126/scisignal.2001906.

28. El Chaar M., Candotti D., Crowther R. A. et al. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010; 52:1600-1610. DOI:10. 1002/hep.23886

29. Pollicino T., Amaddeo G., Restuccia A. et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012; 56:434-443. DOI:10.1002/hep.25592.

30. Hollinger F. B. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008; 48:1001-1026. DOI:10.1111/j.1537-2995.2008.01701.x.

31. Candotti D., Allain J. P. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009; 51:798-809. DOI: https://doi.org/10.1016/j.jhep.2009.05.020.

32. Allain J. P., Cox L. Challenges in hepatitis B detection among blood donors. Curr Opinion Hematol 2011; 18:461-466. DOI: 10.1097/MOH.0b013e32834bac10.

33. Hollinger F. B., Sood G. Occult hepatitis B virus infection: a covert operation. J Viral Hepat 2010; 17:1-15. DOI:10.1111/j.1365-2893.2009.01245.x.

34. Golosova TV, Somova AV, Tupoleva TA et al. Donor testing and evolution of post-transfusion hepatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology 1999; 9:32-36.

35. Allain J. P., Belkhiri D., Vermeulen M. et al. Characterization of occult hepatitis B virus strains in South African blood donors. Hepatology 2009; 49:1868-1876. DOI: 10.1002/hep.22879.

36. Stramer S. L., Wend U., Candotti D. et al. Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364:236-247. DOI: 10.1056/NEJMoa1007644.

37. Esposito A., Sabia C., Iannone C. et al. Occult hepatitis infection in transfusion medicine: screening policy and assessment of current use of anti-HBc testing. Transfus Med Hemother 2017; 44:263-272. doi:10.1159/000460301.

38. Tupoleva T. A., Ignatova E. N., Gulyaeva A. A. et al. Screening of donor blood for antibodies to the core antigen of hepatitis B virus as a tool to improve the safety of transfusions for patients with diseases of the blood system. Clinical laboratory diagnostics 2016; 61:311-316.

39. Tupoleva T. A., Romanova T. Yu., Gulyaeva A. A. Risk of transmission of hepatitis B and C viruses with blood of donors. Hematology and transfusiology 2017; 62:32-36.

40. Chemin I., Guillaud O., Queyron P. C. et al. Close monitoring of serum HBV DNA levels and liver enzymes levels is most useful in the management of patients with occult HBV infection. J Hepatol 2009; 51:824-825. DOI: https://doi.org/10.1016/j.jhep.2009.06.007

41. Komiya Y., Katayama K., Yugi H. et al. Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008; 48:286-294. DOI: 10.1111/j.1537-2995.2007.01522.x

42. Allain J. P., Mihaljevic I., Gonzalez-Fraile M. I. et al. Infectivity of blood products from donors with occult hepatitis B virus infection. Transfusion 2013; 53:1405-1415. DOI: 10.1111/trf.12096.

43. Cheung C. K., Lo C. M., Man K. et al. Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis. Liver Transplant 2010; 16:1314-1323. DOI: 10.1002/lt.22169.

44. Cholongitas E., Papatheodoridis G. V., Burroughs A. K. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatology 2010; 52:272-279. DOI: https://doi.org/10.1016/j.jhep.2009.11.009.

45. Wang Y., Luo X. M., Yang D. et al. Testing for hepatitis B infection in prospective chemotherapy patients: A retrospective study. World J Gastroenterol 2013; 19:923-930. DOI: http://dx.doi.org/10.3748/wjg.v19.i6.923

46. Kusumoto S., Tanaka Y., Mizokami M. et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Inter J Hematol 2009; 90:13-23. DOI: 10.1007/s12185-009-0359-5.

47. Lalazar G., Rund D., Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007; 136:699-712. DOI: 10.1111/j.1365-2141.2006.06465.x.

48. Ritchie D., Piekarz R. L., Blombery P. et al. Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report. Haematologica 2009; 94:1618-1622. doi:10.3324/haematol.2009.008607.

49. Pei S. N., Chen C. H., Lee C. M. et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAgpositive and HBsAg-negative patients. Ann Hematol 2010; 89:255-2. doi: https://doi.org/10.1007/s00277-009-0806-7.

50. Yeo W., Chan T. C., Leung N. W. et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009; 27:605-611. DOI: 10.1200/JCO.2008.18.0182

51. Onozawa M., Hashino S., Izumiyama K. et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005; 79:616-619. DOI: 10.1097/01.TP.0000151661.52601.FB

52. Vigano M., Vener C., Lampertico P. et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transplant 2011; 46:125-131. DOI:10.1038/bmt.2010.70

53. Tupoleva T. A., Garmaeva T. Ts., Kulikov S. M. Protocol for monitoring the virological status of patients with diseases of the blood system in order to implement a strategy to improve the viral safety of transfusions // In the book: Diagnostic algorithms and protocols for the treatment of diseases of the system Blood / Ed. V. G. Savchenko. — M.: Practice, 2018; vol. 1, p. 143-158.

54. Garmaeva T. Ts., Kulikov SM Donors and recipients of blood components as linked objects of study in epidemiological population studies. Ter archive 2015; 87:134-138.

55. Sanchez M. J., Buti M., Homs M. et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol 2009; 51:1091-1096. DOI: 10.1016/j.jhep.2009.07.012

56. Raimondo G., Cacciamo G., Saitta C. Hepatitis B virus and hepatitis C virus co-infection: additive players in chronic liver disease. Ann Hepatol 2005; 4:100-106.

57. Bellecave P., Gouttenoire J., Gajer M. et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009; 50:46-55. DOI: 10.1002/hep.22951.

58. Raimondo G., Navarra G., Mondello S. et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008; 48:743-746. DOI: https://doi.org/10.1016/j.jhep.2008.01.023.

59. Shi Y., Wu Y. H., Wu W. et al. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Intern 2012; 32:231-240. DOI: 10.1111/j.1478-3231.2011.02481.x

60. Fwu C. W., Chien Y. C., You S. L. et al. Hepatitis B virus infection and risk of intrahepatic cholangiocarcinoma and non-Hodgkin lymphoma: a cohort study of parous women in Taiwan. Hepatology 2011; 53:1217-1225. DOI: 10.1002/hep.24150.

4 mandatory analyzes

Comprehensive study combines 4 analyzes required for hospitalization, registration, transfer from / to a medical institution, obtaining a health certificate, obtaining a work permit in the Russian Federation, etc. Studies allow to detect diseases transmitted during medical procedures and sexually: HIV, hepatitis B and C, syphilis. In the case of anonymous delivery of this survey, it is not required to indicate passport data (full name, address of permanent residence, citizenship).

The complex includes:

• HIV 1,2 Ag/Ab Combo (determination of antibodies to HIV types 1 and 2 and p24 antigen)
• Anti-HCV, antibodies, ELISA
• Treponema pallidum, antibodies, ELISA
• HBsAg, ELISA

Synonyms English

Hepatitis C, antibodies + hepatitis B, antigen, Australian antigen + HIV 1 and 2, antibodies and p24 antigen + syphilis (treponema pallidum), antibodies.

Synonyms English

Anti-HCV + HBsAg, Hepatitis B Surface Antigen + HIV 1.2 Ag/Ab Combo,HIV 1.2 Abs, p24 antigen + Treponema pallidum Abs.

Test method

Enzyme immunoassay (ELISA), electrochemiluminescent immunoassay (ECLIA).

What biomaterial can be used for research?

Venous blood.

How to properly prepare for the examination?

• Do not smoke for 30 minutes before the test.

General information about the study

The study is designed to screen for hepatitis B and C , HIV infection types 1 and 2 and syphilis.

For hepatitis B screening, one of the antigens of this virus, HBsAg, is determined in the test. It is part of the virus envelope and is the earliest marker of active infection. HBsAg usually appears in the blood 2-8 weeks after infection. This antigen can be detected in both acute and chronic hepatitis B. It is not detectable in resolution of acute hepatitis B infection and after vaccination. It should be emphasized that HBsAg is also not detected during the “serological window”. Moreover, in some cases, hepatitis infection is latent, with the virus remaining in the liver tissue (as evidenced by a positive viral DNA test), but HBsAg is not detected in the blood. Thus, HBsAg is a sensitive, but not an absolute marker for excluding hepatitis B. The presence of HBsAg in the blood for more than 6 months is one of the criteria for diagnosing chronic hepatitis B. If HBsAg is detected in the blood, additional confirmatory tests are performed to clarify the diagnosis.

For hepatitis C screening, IgG antibodies to this virus are determined in the test. Anti-HCV can be detected in both current infection (acute or chronic) and resolution of acute hepatitis C. Thus, Anti-HCV testing does not differentiate between acute and chronic hepatitis and a history of hepatitis C. If Anti-HCV is detected in the blood, additional confirmatory tests are performed to clarify the diagnosis.

Screening for HIV type 1 and 2 infection is carried out by detection of antibodies to this virus and p24 antigen. The assay for antibodies to the virus is characterized by very high sensitivity (> 99.5%. The specificity of such an analysis is lower: a false positive result can be observed in the presence of autoantibodies in the patient’s blood, liver disease, recent vaccination against the influenza virus, and in the presence of another acute viral infection. For this reason, when a positive result is obtained, an additional confirmatory analysis is performed. Also, to obtain more accurate information about the patient’s HIV status, an analysis for antibodies to HIV is supplemented with an analysis for the p24 antigen, one of the structural proteins of the viral capsid, which is an early marker of acute HIV infection. The analysis for p24 can be especially useful in the early stages of infection, when the titer of antibodies to the virus has not yet reached a detectable level. It should be noted that when a sufficient amount of antibodies to HIV (including p24) is developed, this antigen may no longer be detected. The specificity of the analysis for p24 reaches 100%, and its sensitivity is 30-50%. The combination of two HIV tests (antibodies and p24 antigen) achieves 100% sensitivity and specificity.

For syphilis screening, IgM and IgG antibodies to treponema pallidum (Treponema pallidum) are determined in the test. The assay is characterized by very high sensitivity. With the following factors, false positive results may be observed: the presence of autoantibodies (for example, antinuclear antibodies) in the blood, the presence of acute respiratory viral infections, mononucleosis, measles and other viral infections, periarteritis nodosa, rheumatoid arthritis, scleroderma and other connective tissue diseases, other spirochetosis (Lyme disease, leptospirosis ) and other treponematoses. For this reason, when a positive test result is obtained, additional confirmatory tests are performed to clarify the diagnosis. Serological tests are most informative in the secondary period and with latent syphilis.

Since the test detects antibodies to pathogens, the interpretation of the result should take into account the state of the patient’s immune system. False-negative results may occur in immunosuppressed patients (taking glucocorticoids and other immunosuppressants) and in the elderly. Also of great importance are anamnestic data: the patient’s belonging to the risk group for these diseases (use of injecting drugs, multiple blood transfusions), the presence of autoimmune and infectious diseases, the physiological state of the body (pregnancy, old age).

What is research used for?

• For screening for hepatitis B and C, HIV types 1 and 2, and syphilis.

When is the test scheduled?

• When admitted to a hospital;
• when issuing a sanitary book;
• when registering for pregnancy;
• when registering for military registration;
• when obtaining a work permit.

What do the results mean?

Reference values: negative – for all 4 indicators.

What can influence the result?

• Time since infection;
• state of the body’s immune system;
• the presence in the blood of autoantibodies, viral and bacterial pathogens that prevent the implementation of the reaction.

Important notes

• With HBsAg (hepatitis B), HIV (HIV), HCV (hepatitis C) infections, the incubation period can be up to six months, with Treponema pallidum (syphilis) – up to a month, but everything is individual and depends on the viral and bacterial load and the body’s immune response .

• The study is screening: upon receipt of a positive test result, additional confirmatory tests are performed to clarify the diagnosis;
• when interpreting the result, the state of the patient’s immune system should be taken into account.

Also recommended

• Viral hepatitis B. Screening to rule out hepatitis B virus, including in contacts
• Viral hepatitis B. Determination of the form and stage of the disease
• Viral hepatitis C. Tests for the initial detection of the disease. Examination of contact persons
• Viral hepatitis. Primary diagnosis
• Treponema pallidum, antibodies, hypersensitive
• Treponema pallidum, IgM, titer
• Treponema pallidum, IgG, titer
• Treponema pallidum, DNA [PCR]

Who orders the examination?

General practitioner, internist, surgeon, gynecologist.